Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients.

CONCLUSION: This heterogeneous patient population in a real-world setting had a PFS comparable with what could be expected from the related randomized trial. The de novo patients had better OS and PFS as compared to patients with recurrence.
PMID: 32200206 [PubMed - as supplied by publisher]

Source: Breast - March 12, 2020 Category: Cancer & Oncology Authors: Christensen T, Berg T, Nielsen LB, Andersson M, Jensen MB, Knoop A Tags: Breast Source Type: research